Status
Conditions
Treatments
About
The overall objective is to propose a comprehensive analysis of the biological properties of the stromal vascular fraction evaluated in the SCLERADEC 2 clinical trial (n = 15 available) and preserved in the biological collection, compared to healthy donors (n = 10). This characterization will focus on the exploration of the phenotypic and functional characteristics of the main cellular subpopulations present in the stromal vascular fraction of scleroderma patients likely to be associated with a better regenerative vascular or anti-fibrotic activity of the cell therapy product.
The main objective will be to validate whether the supposed mechanism of action of this innovative therapy, in relation to the representativity of the endothelial progenitors, carrying the vascular regeneration activity, is preserved in the sclerodermic context.
A total of 30 subjects (20 systemic Scleroderma patients and 10 healthy donors) will be included.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with systemic scleroderma:
Healthy volunteers:
Exclusion criteria
Patients with systemic scleroderma:
For healthy patients and volunteers:
30 participants in 2 patient groups
Loading...
Central trial contact
Alexandra GIULIANI; Jérémy MAGALON
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal